{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:54:26Z","timestamp":1790178866733,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008989.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T00:00:00Z","timestamp":1445472000000}}],"reference-count":173,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008989.pub3","type":"journal-article","created":{"date-parts":[[2015,10,23]],"date-time":"2015-10-23T11:50:57Z","timestamp":1445601057000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Long-acting beta<sub>2<\/sub>\n-agonist in addition to tiotropium versus either tiotropium or long-acting beta<sub>2<\/sub>\n-agonist alone for chronic obstructive pulmonary disease"],"prefix":"10.1002","volume":"2015","author":[{"given":"Hugo A","family":"Farne","sequence":"first","affiliation":[{"name":"Imperial College London; National Heart and Lung Institute; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Cates","sequence":"additional","affiliation":[{"name":"St George's, University of London; Population Health Research Institute; Cranmer Terrace London UK SW17 0RE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,10,22]]},"reference":[{"issue":"8","key":"10.1002\/14651858.CD008989.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1155\/2004\/394710","article-title":"The Canadian optimal therapy of COPD trial: design, organization and patient recruitment","volume":"11","author":"Aaron","year":"2004","journal-title":"Canadian Respiratory Journal"},{"issue":"8","key":"10.1002\/14651858.CD008989.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-146-8-200704170-00152","article-title":"Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial","volume":"146","author":"Aaron","year":"2007","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008989.pub3-BIB0003|cit3","first-page":"258","article-title":"Effects of tiotropium combined with either salmeterol or salmeterol\/fluticasone in moderate to severe COPD","volume":"16","author":"Kaplan","year":"2007","journal-title":"Primary Care Respiratory Journal"},{"issue":"11","key":"10.1002\/14651858.CD008989.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/thx.2007.089557","article-title":"Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD","volume":"63","author":"Najafzadeh","year":"2008","journal-title":"Thorax"},{"issue":"6","key":"10.1002\/14651858.CD008989.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0761-8417(07)78518-8","article-title":"Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial","volume":"63","author":"Roisman","year":"2007","journal-title":"Revue de Pneumologie Clinique"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0006|cit6","doi-asserted-by":"crossref","unstructured":"Buhl R Abrahams R Bjermer L Derom E Flezar M Hebert J Pooled safety analysis of once-daily tiotropium and olodaterol fixed-dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1-year studies Chest 2014","DOI":"10.1378\/chest.1994476"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Buhl R Derom E Ferguson G Pizzichini E Reid J Watz H Once-daily tiotropium and olodaterol fixed-dose combination via the Respimat improves outcomes versus mono-components in COPD in two 1-year studies Thorax 2014 A188 9","DOI":"10.1136\/thoraxjnl-2014-206260.382"},{"issue":"4","key":"10.1002\/14651858.CD008989.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1183\/09031936.00136014","article-title":"Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)","volume":"45","author":"Buhl","year":"2015","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0009|cit9","unstructured":"Chia M Reid J Buhl R Abrahams R Bjermer L Derom E Safety of once-daily tiotropium and olodaterol fixed-dose combination via the Respimat in chronic obstructive pulmonary disease in two 1-year studies Respirology 2015 77"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0010|cit10","unstructured":"Chia M Reid J Buhl R Derom E Ferguson G Maltais F Once-daily tiotropium and olodaterol fixed-dose combination via the Respimat improves outcomes vs mono-components in COPD in two 1-year studies Respirology 2015 77"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0011|cit11","unstructured":"NCT01431274 Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/show\/NCT01431274"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Buhl R Abrahams R Bjermer L Derom E Flezar M Hebert J Pooled safety analysis of once-daily tiotropium and olodaterol fixed-dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1-year studies Chest 2014","DOI":"10.1378\/chest.1994476"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0013|cit13","doi-asserted-by":"crossref","unstructured":"Buhl R Derom E Ferguson G Pizzichini E Reid J Watz H Once-daily tiotropium and olodaterol fixed-dose combination via the Respimat improves outcomes versus mono-components in COPD in two 1-year studies Thorax 2014 A188 9","DOI":"10.1136\/thoraxjnl-2014-206260.382"},{"issue":"4","key":"10.1002\/14651858.CD008989.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1183\/09031936.00136014","article-title":"Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)","volume":"45","author":"Buhl","year":"2015","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0015|cit15","unstructured":"Chia M Reid J Buhl R Abrahams R Bjermer L Derom E Safety of once-daily tiotropium and olodaterol fixed-dose combination via the Respimat in chronic obstructive pulmonary disease in two 1-year studies Respirology 2015 77"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0016|cit16","unstructured":"Chia M Reid J Buhl R Derom E Ferguson G Maltais F Once-daily tiotropium and olodaterol fixed-dose combination via the Respimat improves outcomes vs mono-components in COPD in two 1-year studies Respirology 2015 77"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0017|cit17","unstructured":"NCT01431287 Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/show\/NCT01431287"},{"issue":"Suppl 58","key":"10.1002\/14651858.CD008989.pub3-BIB0019|cit18","first-page":"4668","article-title":"Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD","volume":"44","author":"Hoshino","year":"2014","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0018|cit19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/resp.12256","article-title":"Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients","volume":"19","author":"Hoshino","year":"2014","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0020|cit20","unstructured":"A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 \u03bcg once daily with open label tiotropium 18 \u03bcg once daily versus open label tiotropium 18 \u03bcg once daily in patients with moderate-to-severe chronic obstructive pulmonary disease www.novctrd.com\/CtrdWeb\/displaypdf.nov?trialresultid=3901"},{"issue":"4","key":"10.1002\/14651858.CD008989.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/15412555.2012.702004","article-title":"Journal club","volume":"9","author":"Balkissoon","year":"2012","journal-title":"COPD: Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"9","key":"10.1002\/14651858.CD008989.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1136\/thoraxjnl-2011-201140","article-title":"Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison","volume":"67","author":"Mahler","year":"2012","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0023|cit23","doi-asserted-by":"crossref","unstructured":"Mahler DA D'Urzo A Peckitt C Lassen C Kramer B Filcek S Combining once-daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13-18, Denver, Colorado 2011 183","DOI":"10.1164\/ajrccm-conference.2011.183.1_MeetingAbstracts.A1591"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0024|cit24","unstructured":"NCT00846586 Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease clinicaltrials.gov\/show\/NCT00846586"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0025|cit25","unstructured":"A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 \u03bcg once daily with open label tiotropium 18 \u03bcg once daily versus open label tiotropium 18 \u03bcg once daily in patients with moderate-to-severe chronic obstructive pulmonary disease www.novctrd.com\/CtrdWeb\/displaypdf.nov?trialresultid=3901"},{"issue":"4","key":"10.1002\/14651858.CD008989.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/15412555.2012.702004","article-title":"Journal club","volume":"9","author":"Balkissoon","journal-title":"COPD: Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"9","key":"10.1002\/14651858.CD008989.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1136\/thoraxjnl-2011-201140","article-title":"Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison","volume":"67","author":"Mahler","year":"2012","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0028|cit28","doi-asserted-by":"crossref","unstructured":"Mahler DA D'Urzo A Peckitt C Lassen C Kramer B Filcek S Combining once-daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13-18, Denver, Colorado 2011 183","DOI":"10.1164\/ajrccm-conference.2011.183.1_MeetingAbstracts.A1591"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0029|cit29","unstructured":"NCT00877383 Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease clinicaltrials.gov\/show\/NCT00877383"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0030|cit30","unstructured":"NCT00139932 Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272) ClinicalTrials.gov\/show\/NCT00139932"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD008989.pub3-BIB0031|cit31","first-page":"S4 [13]","article-title":"Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]","volume":"119","author":"Tashkin","year":"2007","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"4","key":"10.1002\/14651858.CD008989.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"529a","DOI":"10.1378\/chest.132.4_MeetingAbstracts.529a","article-title":"The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12-week, multicenter, double-blind, placebo-controlled, trial","volume":"132","author":"Tashkin","year":"2007","journal-title":"Chest"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0035|cit33","first-page":"A647[#F5]","article-title":"Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]","author":"Tashkin","year":"2008","journal-title":"American Thoracic Society International Conference; 2008 May 16-21; Toronto"},{"issue":"1","key":"10.1002\/14651858.CD008989.pub3-BIB0033|cit34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/15412550902724073","article-title":"Formoterol and tiotropium compared with tiotropium alone for treatment of COPD","volume":"6","author":"Tashkin","year":"2009","journal-title":"COPD: Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"4","key":"10.1002\/14651858.CD008989.pub3-BIB0034|cit35","doi-asserted-by":"crossref","first-page":"103002s","DOI":"10.1378\/chest.134.4_MeetingAbstracts.p103002","article-title":"Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]","volume":"134","author":"Tashkin","year":"2008","journal-title":"Chest"},{"issue":"Suppl 50","key":"10.1002\/14651858.CD008989.pub3-BIB0036|cit36","first-page":"440s [P2514]","article-title":"Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]","volume":"28","author":"Arievich","year":"2006","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0037|cit37","unstructured":"NCT00134979 Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co-administration of olodaterol Respimat\u00ae and tiotropium HandiHaler\u00ae clinicaltrials.gov\/show\/NCT00134979"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0038|cit38","unstructured":"Novartis A randomized, multi-center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10\u03bcg b.i.d., tiotropium HandiHaler 18\u03bcg o.d. and tiotropium HandiHaler 18\u03bcg o.d. in combination with formoterol Certihaler 10\u03bcg b.i.d. in patients with stable chronic obstructive pulmonary disease www.novctrd.com\/CtrdWeb\/displaypdf.nov?trialresultid=1591"},{"issue":"11","key":"10.1002\/14651858.CD008989.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.rmed.2008.07.020","article-title":"Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study","volume":"102","author":"Vogelmeier","year":"2008","journal-title":"Respiratory Medicine"},{"issue":"Suppl 50","key":"10.1002\/14651858.CD008989.pub3-BIB0040|cit40","first-page":"429s [P2506]","article-title":"Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]","volume":"28","author":"Vogelmeier","year":"2006","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0041|cit41","doi-asserted-by":"crossref","unstructured":"Abrahams R Allen L Hernandez G Ting N ZuWallack R Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12-week studies Chest 2014 47A 10.1378\/chest.1994418","DOI":"10.1378\/chest.1994418"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0042|cit42","unstructured":"NCT01694771 Co-administration of olodaterol Respimat\u00ae and tiotropium HandiHaler\u00ae clinicaltrials.gov\/show\/NCT01694771"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"70A","DOI":"10.1378\/chest.1994318","article-title":"Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double-blind studies","volume":"146 (4 meeting","author":"ZuWallack","year":"2014","journal-title":"Chest"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2147\/COPD.S72482","article-title":"Efficacy and safety of combining olodaterol Respimat(\u00ae) and tiotropium HandiHaler(\u00ae) in patients with COPD: results of two randomized, double-blind, active-controlled studies","volume":"9","author":"ZuWallack","year":"2014","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0045|cit45","first-page":"46A","article-title":"Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double-blind studies","volume":"146 (4 meeting","author":"ZuWallack","year":"2014","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0046|cit46","doi-asserted-by":"crossref","unstructured":"Abrahams R Allen L Hernandez G Ting N Wallack RZ Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12-week studies Chest 47A","DOI":"10.1378\/chest.1994418"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0047|cit47","unstructured":"NCT01696058 Co-administration of olodaterol Respimat\u00ae and tiotropium HandiHaler\u00ae clinicaltrials.gov\/show\/NCT01696058"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"70A","DOI":"10.1378\/chest.1994318","article-title":"Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double-blind studies","volume":"146 (4 meeting","author":"ZuWallack","year":"2014","journal-title":"Chest"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2147\/COPD.S72482","article-title":"Efficacy and safety of combining olodaterol Respimat(\u00ae) and tiotropium HandiHaler(\u00ae) in patients with COPD: results of two randomized, double-blind, active-controlled studies","volume":"9","author":"ZuWallack","year":"2014","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0050|cit50","first-page":"46A","article-title":"Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double-blind studies","volume":"146 (4 meeting","author":"ZuWallack","year":"2014","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"Suppl 56","key":"10.1002\/14651858.CD008989.pub3-BIB0051|cit51","first-page":"P2882","article-title":"Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat inhaler in patients with COPD","volume":"40","author":"Aalbers","year":"2012","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0052|cit52","first-page":"3","article-title":"Once-daily dual bronchodilation with QVA149 reduces COPD exacerbations: results from the ignite program","volume":"145 (meeting ab","author":"Banerji","year":"2014","journal-title":"Chest"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD008989.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"A147","DOI":"10.1136\/thoraxjnl-2012-202678.253","article-title":"QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study [Abstract]","volume":"67","author":"Barnes","year":"2012","journal-title":"Thorax"},{"issue":"Suppl 33","key":"10.1002\/14651858.CD008989.pub3-BIB0054|cit54","first-page":"26s","article-title":"A comparative trial of tiotropium, salmeterol and placebo: health-related quality of life","volume":"18","author":"Bateman","year":"2001","journal-title":"European Respiratory Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD008989.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"A148","DOI":"10.1136\/thoraxjnl-2012-202678.254","article-title":"Glycopyrronium once daily provides rapid and sustained bronchodilation and is well tolerated in patients with COPD: the SHINE study [Abstract]","volume":"67","author":"Bateman","year":"2012","journal-title":"Thorax"},{"issue":"Suppl 56","key":"10.1002\/14651858.CD008989.pub3-BIB0056|cit56","first-page":"2810","article-title":"Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study [Abstract]","volume":"40","author":"Bateman","year":"2012","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0057|cit57","first-page":"A4263","article-title":"Dual bronchodilation with once-daily QVA149 provides superior bronchodilation compared to its mono-components and tiotropium in all subgroups of patients with COPD: the SHINE study","volume":"187","author":"Bateman","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD008989.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1183\/09031936.00200212","article-title":"Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study","volume":"42","author":"Bateman","year":"2013","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0059|cit59","first-page":"A147 [P191]","article-title":"QVA149 once daily improves exercise tolerance and lung function in patients with moderate to severe COPD: the BRIGHT study [Abstract]","volume":"67 (Suppl 2)","author":"Beeh","year":"2012","journal-title":"Thorax"},{"issue":"4","key":"10.1002\/14651858.CD008989.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.rmed.2014.01.006","article-title":"Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study","volume":"108","author":"Beeh","year":"2014","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2147\/COPD.S26100","article-title":"Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients","volume":"7","author":"Beier","year":"2012","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0062|cit62","unstructured":"Brusasco V Menjoge SS Kesten S Flow and volume responders following treatment with tiotropium and salmeterol in patients with COPD [Abstract] Proceedings of the American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle 2003 B024 Poster 420"},{"issue":"10","key":"10.1002\/14651858.CD008989.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.rmed.2012.05.012","article-title":"Addition of tiotropium to formoterol improves inspiratory muscle strength after exercise in COPD","volume":"106","author":"Canto","year":"2012","journal-title":"Respiratory Medicine"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD008989.pub3-BIB0064|cit64","first-page":"31 [OS100]","article-title":"Once-daily QVA149 improves lung function, dyspnea and health status regardless of disease severity and prior medications: the SHINE study [Abstract]","volume":"18","author":"Chapman","year":"2013","journal-title":"Respirology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008989.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"A182","DOI":"10.1136\/thoraxjnl-2013-204457.386","article-title":"P234 QVA149 once daily improves lung function, dyspnoea and health status independent of prior medications and disease severity: the SHINE study","volume":"68","author":"Chapman","year":"2013","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0066|cit66","doi-asserted-by":"crossref","DOI":"10.1378\/chest.1813585","article-title":"Once-daily QVA149 improves lung function, dyspnea, and health status independent of disease severity and prior medications: the SHINE study","volume":"145","author":"Chapman","year":"2014","journal-title":"Chest"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"P236","DOI":"10.1136\/thoraxjnl-2013-204457.388","article-title":"Superior lung function with once-daily QVA149 translates into improvements in patient-reported breathlessness compared with placebo and tiotropium in COPD patients: the BLAZE study","volume":"68","author":"D'Urzo","year":"2013","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0068|cit68","article-title":"Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: the BLAZE study","volume":"145 (3 meeting","author":"D'Urzo","year":"2014","journal-title":"Chest"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0069|cit69","article-title":"Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: the BLAZE study","volume":"145 (3 meeting","author":"D'Urzo","year":"2014","journal-title":"Chest"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0070|cit70","first-page":"A1479","article-title":"Safety and tolerability of QVA149, glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study","volume":"187 (meeting ab","author":"Decramer","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"A190","DOI":"10.1136\/thoraxjnl-2014-206260.386","article-title":"The 24-hour lung function profile of once-daily tiotropium and olodaterol fixed-dose combination compared with placebo and monotherapies in chronic obstructive pulmonary disease","volume":"69","author":"Derom","year":"2014","journal-title":"Thorax"},{"issue":"Suppl 45","key":"10.1002\/14651858.CD008989.pub3-BIB0072|cit72","first-page":"P1844","article-title":"A single dose of formoterol (FOR) and tiotropium (TIO) reduce hyperinflation in COPD patients [Abstract]","volume":"22","author":"Marco","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0073|cit73","article-title":"QVA149 improves lung function and reduces exacerbations compared with tiotropium in patients with severe-to-very severe COPD: the SPARK study","volume":"145 (3 meeting","author":"Ficker","year":"2014","journal-title":"Chest"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD008989.pub3-BIB0074|cit74","first-page":"20 [O041]","article-title":"Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study [Abstract]","volume":"18","author":"Frith","year":"2013","journal-title":"Respirology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD008989.pub3-BIB0075|cit75","first-page":"A164","article-title":"Comparison of clinical efficacy of tiotropium and salmeterol for pulmonary function, air-trapping, exercise capacity, and HRQO in COPD [Abstract]","volume":"12","author":"Fujimoto","year":"2007","journal-title":"Respirology"},{"issue":"Suppl 58","key":"10.1002\/14651858.CD008989.pub3-BIB0076|cit76","first-page":"P897","article-title":"Efficacy of tiotropium and indacaterol alone or the combination on dynamic lung hyperinflation and exercise tolerance in COPD [Abstract]","volume":"44","author":"Fujimoto","year":"2014","journal-title":"European Respiratory Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008989.pub3-BIB0077|cit77","first-page":"101","article-title":"Efficacy of mono-therapy with tiotropium or indacaterol or the","volume":"19","author":"Fujimoto","year":"2014","journal-title":"Respirology (Carlton, Vic.)"},{"issue":"11","key":"10.1002\/14651858.CD008989.pub3-BIB0078|cit78","first-page":"1081","article-title":"A comparison of maintenance tiotropium and salmeterol on arterial blood gas tensions in patients with COPD [Abstract]","volume":"48","author":"Gross","year":"2003","journal-title":"Respiratory Care"},{"issue":"4","key":"10.1002\/14651858.CD008989.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1208\/s12248-015-9751-7","article-title":"In vitro, pharmacokinetic, pharmacodynamic, and safety comparisons of single and combined administration of tiotropium and salmeterol in COPD patients using different dry powder inhalers","volume":"17","author":"Horhota","year":"2015","journal-title":"AAPS Journal"},{"issue":"2","key":"10.1002\/14651858.CD008989.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/2045-080X.155509","article-title":"Combinations of long acting beta2 agonists to","volume":"6","author":"Imran","year":"2015","journal-title":"Archives of Pharmacy Practice"},{"issue":"4","key":"10.1002\/14651858.CD008989.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3109\/15412555.2013.771162","article-title":"Combined therapy with tiotropium and formoterol in chronic obstructive pulmonary disease: effect on the 6-minute walk test","volume":"10","author":"Jayaram","year":"2013","journal-title":"Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0082|cit82","unstructured":"Jones CDS The combined effect of tiotropium and formoterol on the functional status of patients with moderate-to-severe COPD [Dissertation] CINAHL Accession Number: 2011033276\/\/UMI Order AAI3408930 2010 144 p"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0083|cit83","first-page":"A6070","article-title":"Superior lung function with once-daily QVA149 translates into improvements in patient-reported breathlessness compared with placebo and tiotropium in COPD patients: the BLAZE study","volume":"187","author":"Mahler","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD008989.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1183\/09031936.00124013","article-title":"Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study","volume":"43","author":"Mahler","year":"2014","journal-title":"European Respiratory Journal"},{"issue":"12","key":"10.1002\/14651858.CD008989.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.rmed.2014.10.002","article-title":"Efficacy and safety of umeclidinium\/vilanterol 62.5\/25 mcg and tiotropium 18 mcg","volume":"108","author":"Maleki-Yazdi","year":"2014","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0086|cit86","unstructured":"Meyer T Brand P Reitmeir P Scheuch G Effect of formoterol, salbutamol and tiotropium bromide on the efficacy of lung clearance in patients with COPD [Abstract] Proceedings of the American Thoracic Society International Conference; 2008 May 16-21; Toronto 2008 A646[#F1]"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0087|cit87","doi-asserted-by":"crossref","DOI":"10.1378\/chest.1824325","article-title":"LABA\/LAMA dual bronchodilation as a paradigm shift in COPD therapy: overview of the QVA149 ignite program","volume":"145","author":"Mezzi","year":"2014","journal-title":"Chest"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0088|cit88","doi-asserted-by":"crossref","unstructured":"Mezzi K Wedzicha JA Decramer M Fowler Taylor A Fogel R Chen H QVA149 provides greater improvement in patient reported symptom scores compared to glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study [Abstract] Proceedings of the 7th International Primary Care Respiratory Group (IPCRG) World Conference Athens 2014","DOI":"10.1378\/chest.1824414"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0089|cit89","unstructured":"NCT00394485 Tiotropium + procaterol vs tiotropium + placebo in COPD patients clinicaltrials.gov\/show\/NCT00394485"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0090|cit90","unstructured":"NCT00424528 Efficacy safety study of arformoterol\/tiotropium combination versus either therapy alone in chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/show\/NCT00424528"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0091|cit91","unstructured":"NCT00668772 Tiotropium\/salmeterol inhalation powder in COPD clinicaltrials.gov\/show\/NCT00668772"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0092|cit92","unstructured":"NCT00673478 Tiotropium and salmeterol PK study in COPD patients clinicaltrials.gov\/show\/NCT00673478"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0093|cit93","unstructured":"NCT00680056 Add-on effects of tiotropium over formoterol in exercise tolerance on chronic obstructive pulmonary disease patients clinicaltrials.gov\/show\/NCT00680056"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0094|cit94","unstructured":"NCT00696020 Combination of orally inhaled BI1744CL\/tiotropium bromide in patients with chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/show\/NCT00696020"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0095|cit95","unstructured":"NCT01040403 Determining optimal free dose combination of tiotropium bromide and BI 1744 CL in chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/show\/NCT01040403"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0096|cit96","unstructured":"NCT01285492 A 52-week treatment, multi-center, randomized, open label, parallel group study to assess the long term safety and tolerability of QVA149 (110 mcg indacaterol \/ 50 mcg glycopyrrolate o.d.) using tiotropium (18 mcg o.d.) as an active control in Japanese patients with moderate to severe chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/show\/NCT01285492"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0097|cit97","unstructured":"NCT01559116 Characterization of 24-hour lung function profiles of inhaled tiotropium + olodaterol fixed dose combination in patients suffering from chronic obstructive pulmonary disease clinicaltrials.gov\/show\/NCT01559116"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0098|cit98","unstructured":"NCT02238119 Efficacy and safety of free combination of tiotropium + formoterol compared to formoterol and tiotropium in patients with chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/show\/NCT02238119"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0099|cit99","unstructured":"NCT02242240 Lung function changes following the addition of formoterol to tiotropium in patients with chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/show\/NCT02242240"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0100|cit100","unstructured":"NCT02242253 Free combinations of tiotropium inhalation powder capsule + salmeterol metered dose inhaler, tiotropium inhalation powder capsule and salmeterol metered dose inhaler in patients with chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/show\/NCT02242253"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0101|cit101","doi-asserted-by":"crossref","unstructured":"New J Hanania N Matovinovic E Tashkin D Adding nebulized formoterol to tiotropium treatment provides added benefits in pulmonary function, dyspnea and rescue medication use: a pooled analysis [Abstract] Proceedings of the American Thoracic Society International Conference; 2009 May 15-20; San Diego 2009 A4541 [Poster #J51]","DOI":"10.1164\/ajrccm-conference.2009.179.1_MeetingAbstracts.A4541"},{"issue":"1","key":"10.1002\/14651858.CD008989.pub3-BIB0102|cit102","first-page":"26","article-title":"Short term effects of tiotropium on COPD patients treated with long acting bronchodilators","volume":"11","author":"Nicolini","year":"2012","journal-title":"Tanaffos"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0103|cit103","first-page":"A3759","article-title":"Combination glycopyrronium and formoterol fumarate inhalation aerosol (PT003) at a dose of 14.4\/9.6 \u00b5g provides superior improvement in inspiratory capacity compared to tiotropium dry powder inhaler (DPI) in subjects with moderate to severe COPD (Abstract)","volume":"189","author":"Orevillo","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0104|cit104","doi-asserted-by":"crossref","unstructured":"Reisner C Fernandez C Orevillo C St. Rose E Kollar C Pearl therapeutics' combination LAMA\/LABA MDI (GFF MDI, PT003) provides comparable metabolic and ECG safety to Spiriva(R) HandiHaler(R) and placebo in patients with COPD Proceedings of the American Thoracic Society 2012 International Conference, 2012 May 18-23; San Francisco, California 2012 A2926","DOI":"10.1164\/ajrccm-conference.2012.185.1_MeetingAbstracts.A2925"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0105|cit105","first-page":"A2259","article-title":"Pearl Therapeutics' combination LAMA\/LABA MDI (GFF-MDI, PT003) provides a significant benefit on home peak expiratory flow rate (PEFR) and reduces the need for rescue albuterol use compared io its components administered alone, Spiriva(R) Handihaler(R), and Foradil(R) Aerolizer(R) in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD [Abstract]","volume":"185","author":"Reisner","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0106|cit106","first-page":"A2434","article-title":"Low doses of Pearl Therapeutics' LAMA\/LABA combination MDI (GFF MDI, PT003) provide superior bronchodilation compared to components and to open-label Spiriva HandiHaler in a randomized, double-blind, placebo-controlled phase IIb study in patients with COPD","volume":"187 (meeting ab","author":"Reisner","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008989.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pupt.2013.05.010","article-title":"Bronchodilator efficacy of tiotropium-formoterol via single pressurized meter dose inhaler (pMDI) versus tiotropium alone in COPD","volume":"27","author":"Salvi","year":"2014","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"issue":"Suppl 58","key":"10.1002\/14651858.CD008989.pub3-BIB0108|cit108","first-page":"P896","article-title":"The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status [Abstract]","volume":"44","author":"Setoguchi","year":"2014","journal-title":"European Respiratory Journal"},{"issue":"11","key":"10.1002\/14651858.CD008989.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1007\/s12325-009-0080-z","article-title":"Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease","volume":"26","author":"Tashkin","year":"2009","journal-title":"Advances in Therapy"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0110|cit110","first-page":"Poster #M72","article-title":"Bronchodilation improves endurance but not muscular efficiency in COPD [Abstract]","author":"Hacken","year":"2007","journal-title":"Proceedings of the American Thoracic Society International Conference; 2007 May 18-23; San Francisco"},{"issue":"Suppl 45","key":"10.1002\/14651858.CD008989.pub3-BIB0111|cit111","first-page":"153","article-title":"Relation between the acute response to salbutamol and long term FEV1 responses to tiotropium (TIO), formoterol (FORM) and its combination (T=F) in COPD patients [abstract]","volume":"22","author":"Noord","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0112|cit112","first-page":"B024 Poster 421","article-title":"Comparison of once daily tiotropium, twice daily formoterol and the free combination, once daily, in patients with COPD [abstract]","author":"Noord","year":"2003","journal-title":"Proceedings of the American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0113|cit113","unstructured":"van Noord JA Smeets JJ Otte A Bindels H Mueller A Cornellissen PJG The effect of tiotropium, salmeterol and it's combination on dynamic hyperinflation in COPD [Abstract] Proceedings of the American Thoracic Society 2005 International Conference; 2005 May 20-25; San Diego, California 2005 [B93] [Poster: 310]"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0114|cit114","first-page":"81","article-title":"Effect of QVA149 on lung function in the subgroup of patients","volume":"20","author":"Wark","year":"2015","journal-title":"Respirology (Carlton, Vic.)"},{"issue":"3","key":"10.1002\/14651858.CD008989.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","article-title":"Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study","volume":"1","author":"Wedzicha","year":"2013","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0116|cit116","first-page":"A2429","article-title":"Efficacy and safety of QVA149 versus glycopyrronium and tiotropium in severe to very severe COPD: the SPARK study","volume":"187 (meeting ab","author":"Wedzicha","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0117|cit117","first-page":"A3761","article-title":"Qva149 provides greater improvement in patient reported symptom scores compared to glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study [Abstract]","volume":"189","author":"Wedzicha","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008989.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"406A","DOI":"10.1378\/chest.1824370","article-title":"Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: the SPARK study","volume":"145","author":"Wedzicha","year":"2014","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD008989.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"427A","DOI":"10.1378\/chest.1824414","article-title":"Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: the SPARK study","volume":"145","author":"Wedzicha","year":"2014","journal-title":"Chest"},{"issue":"Suppl 58","key":"10.1002\/14651858.CD008989.pub3-BIB0120|cit120","first-page":"1893","article-title":"QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: the SPARK study [Abstract]","volume":"44","author":"Wedzicha","year":"2014","journal-title":"European Respiratory Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD008989.pub3-BIB0121|cit121","first-page":"251","article-title":"Clinical efficacy and safety of tiotropium and indacaterol administration in patient with chronic heart failure due to coronary artery disease combined with chronic obstructive pulmonary disease","volume":"16","author":"Evdokimov","year":"2014","journal-title":"European Journal of Heart Failure Abstracts Supplement"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0122|cit122","first-page":"385","article-title":"Efficacy and safety of different types of bronchodilator therapy in patients with chronic heart failure due to coronary artery disease combined with chronic obstructive pulmonary disease","volume":"35","author":"Evdokimov","year":"2014","journal-title":"European Heart Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008989.pub3-BIB0123|cit123","first-page":"68","article-title":"Clinical efficacy and safety of formoterol and tiotropium administration in patient with chronic heart failure due to coronary artery disease combined with chronic obstructive pulmonary disease","volume":"17","author":"Evdokimov","year":"2015","journal-title":"European Journal of Heart Failure"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0124|cit124","doi-asserted-by":"crossref","unstructured":"Maltais F Galdiz Iturri JB Kirsten A Singh D Hamilton A Tetzlaff K Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD Thorax 2014 A186 7","DOI":"10.1136\/thoraxjnl-2014-206260.378"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0125|cit125","doi-asserted-by":"crossref","unstructured":"Maltais F Iturri JBG Kirsten A Singh D Hamilton A Tetzlaff K Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD European Respiratory Journal 2014","DOI":"10.1136\/thoraxjnl-2014-206260.378"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0126|cit126","unstructured":"NCT01525615 A study to determine the effect of tiotropium + olodaterol fixed dose combination on exercise endurance time during constant work load cycle test in COPD clinicaltrials.gov\/show\/NCT01525615"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0127|cit127","unstructured":"NCT01536262 Japan long-term safety for tiotropium plus olodaterol clinicaltrials.gov\/show\/NCT01536262"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0128|cit128","unstructured":"NCT01964352 Tiotropium + olodaterol fixed dose combination (FDC) in chronic obstructive pulmonary disease (OTEMTO 1) clinicaltrials.gov\/show\/NCT01964352"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0129|cit129","unstructured":"NCT02006732 Tiotropium + olodaterol fixed dose combination (FDC) in chronic obstructive pulmonary disease (OTEMTO 2) clinicaltrials.gov\/show\/NCT02006732"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0130|cit130","unstructured":"NCT02296138 Comparing the efficacy of tiotropium + olodaterol (5\/5 \u00b5g) fixed dose combination (FDC) over tiotropium 5\u00b5g in reducing moderate to severe exacerbations in patients with severe to very severe chronic obstructive pulmonary disease clinicaltrials.gov\/show\/NCT02296138"},{"issue":"3","key":"10.1002\/14651858.CD008989.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"425A","DOI":"10.1378\/chest.1834832","article-title":"Analysis of chronic obstructive pulmonary disease exacerbations with the triple therapy compared with dual and single bronchodilator therapy: which treatment is better for patients with severe disease?","volume":"145","author":"Sadigov","year":"2014","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD008989.pub3-BIB0132|cit132","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001104.pub2","article-title":"Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease","author":"Appleton","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD008989.pub3-BIB0133|cit133","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002876.pub2","article-title":"Tiotropium for stable chronic obstructive pulmonary disease","author":"Barr","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD008989.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s12325-009-0044-3","article-title":"Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases","volume":"26","author":"Beeh","year":"2009","journal-title":"Advances in Therapy"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0135|cit135","first-page":"237","article-title":"Long-acting beta-adrenoceptor agonists in the management of COPD: focus on indacaterol","volume":"6","author":"Beier","year":"2011","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"2","key":"10.1002\/14651858.CD008989.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.rmed.2007.09.011","article-title":"Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease","volume":"102","author":"Berger","year":"2008","journal-title":"Respiratory Medicine"},{"issue":"10","key":"10.1002\/14651858.CD008989.pub3-BIB0137|cit137","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010798","article-title":"Glycopyrronium bromide for chronic obstructive pulmonary disease","author":"Burke","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD008989.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008989.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1124\/jpet.111.179259","article-title":"Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol","volume":"337","author":"Casarosa","year":"2011","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD008989.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.pupt.2010.03.003","article-title":"The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD","volume":"23","author":"Cazzola","year":"2010","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0141|cit141","doi-asserted-by":"crossref","unstructured":"Celli B Decramer M Leimer I Vogel U Kesten S Tashkin DP Cardiovascular safety of tiotropium in patients with COPD Chest 2010 20 30","DOI":"10.1378\/chest.09-0011"},{"issue":"9","key":"10.1002\/14651858.CD008989.pub3-BIB0142|cit142","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009552.pub2","article-title":"Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease","author":"Cheyne","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD008989.pub3-BIB0143|cit143","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009157.pub2","article-title":"Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease","author":"Chong","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0144|cit144","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for diagnosis, management, and prevention of COPD updated 2015 www.goldcopd.org\/uploads\/users\/files\/GOLD_Report_2015.pdf"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0145|cit145","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] Available from www.cochrane-handbook.org"},{"issue":"5","key":"10.1002\/14651858.CD008989.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1445-5994.2010.02195.x","article-title":"Acute care costs of patients admitted for management of chronic obstructive pulmonary disease exacerbations: contribution of disease severity, infection and chronic heart failure","volume":"40","author":"Hutchinson","year":"2010","journal-title":"Internal Medicine Journal"},{"issue":"5 Pt 3","key":"10.1002\/14651858.CD008989.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.1164\/ajrccm.158.supplement_2.13tac110","article-title":"The beta-adrenoceptor","volume":"158","author":"Johnson","year":"1998","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"9","key":"10.1002\/14651858.CD008989.pub3-BIB0148|cit148","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009039.pub2","article-title":"The effect of adding inhaled corticosteroids to tiotropium and long-acting beta2-agonists for chronic obstructive pulmonary disease","author":"Karner","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008989.pub3-BIB0149|cit149","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008532.pub2","article-title":"Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease","author":"Karner","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD008989.pub3-BIB0150|cit150","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009285.pub3","article-title":"Tiotropium versus placebo for chronic obstructive pulmonary disease","author":"Karner","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD008989.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1183\/09031936.00104606","article-title":"Premature discontinuation of patients: a potential bias in COPD clinical trials","volume":"30","author":"Kesten","year":"2007","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0152|cit152","doi-asserted-by":"crossref","unstructured":"Kew KM Dias S Cates CJ Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis Cochrane Database of Systematic Reviews 2014 10.1002\/14651858.CD010844.pub2","DOI":"10.1002\/14651858.CD010844.pub2"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/COPD.S62502","article-title":"Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat(R) versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies","volume":"9","author":"Koch","year":"2014","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"2","key":"10.1002\/14651858.CD008989.pub3-BIB0154|cit154","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003793.pub3","article-title":"Pulmonary rehabilitation for chronic obstructive pulmonary disease","author":"McCarthy","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"17","key":"10.1002\/14651858.CD008989.pub3-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.2165\/11203960-000000000-00000","article-title":"Indacaterol: in chronic obstructive pulmonary disease","volume":"70","author":"Moen","year":"2010","journal-title":"Drugs"},{"issue":"11","key":"10.1002\/14651858.CD008989.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/thx.2007.089557","article-title":"Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD","volume":"63","author":"Najafzadeh","year":"2008","journal-title":"Thorax"},{"issue":"9","key":"10.1002\/14651858.CD008989.pub3-BIB0157|cit157","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010509.pub2","article-title":"Aclidinium bromide for stable chronic obstructive pulmonary disease","author":"Ni","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0158|cit158","unstructured":"National Institute for Health and Clinical Excellence Chronic obstructive pulmonary disease. Costing report. Implementing NICE guidance www.nice.org.uk\/guidance\/cg101\/resources\/cg101-chronic-obstructive-pulmonary-disease-update-costing-report2"},{"issue":"4","key":"10.1002\/14651858.CD008989.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1513\/pats.200504-038SR","article-title":"Beta2-agonist and anticholinergic drugs in the treatment of lung disease","volume":"2","author":"Proskocil","year":"2005","journal-title":"Proceedings of the American Thoracic Society"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0160|cit160","unstructured":"The Nordic Cochrane Centre; The Cochrane Collaboration Review Manager (RevMan) 2012"},{"issue":"5","key":"10.1002\/14651858.CD008989.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1378\/chest.07-1167","article-title":"Safety of long-acting \u03b2-agonists in stable COPD","volume":"133","author":"Rodrigo","year":"2008","journal-title":"Chest"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0162|cit162","unstructured":"Jones P St George's Respiratory Questionnaire for COPD patients (SGRQ-C) www.healthstatus.sgul.ac.uk\/SGRQ_download\/SGRQ-C%20uk%20orig%202005.pdf"},{"issue":"2","key":"10.1002\/14651858.CD008989.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/ebm.14.2.42","article-title":"Review: inhaled anticholinergics increase risk of major cardiovascular events in COPD","volume":"14","author":"Singh","year":"2009","journal-title":"Evidence Based Medicine"},{"issue":"7","key":"10.1002\/14651858.CD008989.pub3-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1440-1681.2005.04222.x","article-title":"New insights into beta-adrenoceptors in smooth muscle: distribution of receptor subtypes and molecular mechanisms triggering muscle relaxation","volume":"32","author":"Tanaka","year":"2005","journal-title":"Clinical and Experimental Pharmacology and Physiology"},{"issue":"15","key":"10.1002\/14651858.CD008989.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A 4-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"New England Journal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008989.pub3-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.rmed.2007.12.019","article-title":"Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial","volume":"102","author":"Tashkin","year":"2008","journal-title":"Respiratory Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008989.pub3-BIB0167|cit167","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002999","article-title":"Smoking cessation for chronic obstructive pulmonary disease","author":"Meer","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD008989.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00059-002-2434-z","article-title":"The beta-adrenergic receptors","volume":"27","author":"Wallukat","year":"2002","journal-title":"Herz"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0169|cit169","doi-asserted-by":"crossref","unstructured":"Welsh EJ Cates CJ Poole P Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease Cochrane Database of Systematic Reviews 2013 10.1002\/14651858.CD007891.pub3","DOI":"10.1002\/14651858.CD007891.pub3"},{"key":"10.1002\/14651858.CD008989.pub3-BIB0170|cit170","unstructured":"World Health Organization Chronic respiratory diseases: chronic obstructive pulmonary disease (COPD) www.who.int\/respiratory\/copd\/en\/"},{"issue":"16","key":"10.1002\/14651858.CD008989.pub3-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa1303342","article-title":"Tiotropium Respimat inhaler and the risk of death in COPD","volume":"369","author":"Wise","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008989.pub3-BIB0172|cit172","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002990.pub3","article-title":"Self management for patients with chronic obstructive pulmonary disease","author":"Zwerink","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD008989.pub3-BIB0173|cit173","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008989.pub2","article-title":"Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease","author":"Karner","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD008989.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T18:35:23Z","timestamp":1661884523000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008989.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,10,22]]},"references-count":173,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008989.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,22]]}}}